Durable clinical benefit observed in recurrent ovarian cancer patients treated with combination pembrolizumab, cyclophosphamide and bevacizumab are associated with increased T and B cell clusters, distinct microbial patterns, and altered metabolism.
- Spencer R. Rosario
- Mark D. Long
- Emese Zsiros
